Skip to main content
Navamedic logo

Navamedic — Investor Relations & Filings

Ticker · NAVA ISIN · NO0010205966 LEI · 529900LKVQOR2SRUJU71 OL Wholesale and retail trade
Open in API
Filings indexed 825 across all filing types
Latest filing 2019-02-27 Share Issue/Capital Cha…
Country NO Norway
Listing OL NAVA

About Navamedic

https://navamedic.com/

Navamedic is a pharmaceutical company that develops, produces, and commercializes a diverse portfolio of medicines and related health products. The company's offerings include specialty pharmaceuticals, branded generics, and consumer health items. Its product portfolio addresses various medical needs, with treatments for conditions such as obesity, Parkinson's disorder, and inborn errors of metabolism, in addition to antibiotics. Serving as a reliable supplier and distribution partner, Navamedic provides high-quality products to hospitals and pharmacies, with a strong presence in the Nordic region and the Netherlands. The company focuses on improving patient outcomes through innovations, including advancements in personalized treatment for Parkinson's care.

Recent filings

Filing Released Lang Actions
Navamedic has completed the acquisition of Novicus Pharma
Share Issue/Capital Change Classification · 99% confidence The document explicitly announces the completion of an acquisition (Navamedic acquiring Novicus Pharma) and details the resulting capital structure change: the issuance of 1,000,000 new shares as consideration. This action directly relates to changes in the company's capital structure and share count. This aligns best with the 'Share Issue/Capital Change' definition (SHA). It is not a general financing update (CAP) because it is a specific transaction resulting in new share issuance, nor is it a transaction in own shares (POS) as it involves issuing new shares for an acquisition, not repurchasing or selling treasury stock.
2019-02-27 English
Navamedic ASA: Trade by primary insider
Director's Dealing Classification · 99% confidence The document explicitly states 'Trade by primary insider' and details a transaction where the Chief Financial Officer (CFO) acquired shares in Navamedic ASA. This directly corresponds to the definition of Director's Dealing (insider trades by executives). The appropriate code is DIRS.
2019-02-14 English
Navamedic ASA: Q4 2018 financial results
Investor Presentation Classification · 99% confidence The document text explicitly states "Fourth quarter results 2018 Navamedic ASA" and contains detailed financial tables comparing Q4 2018 results with Q4 2017, including revenue, gross margin, EBITDA, balance sheet items, and cash flow statements. This structure is characteristic of a periodic financial report covering a period shorter than a full year (Q4). Since it is a comprehensive report for a period shorter than a year, it fits the definition of an Interim / Quarterly Report (IR). It is not an Earnings Release (ER) because it contains extensive financial statements and operational details, not just highlights.
2019-02-14 Norwegian
Navamedic ASA: Q4 2018 financial results
Earnings Release Classification · 100% confidence The document is titled "Navamedic ASA: Q4 2018 financial results" and provides key financial metrics for the fourth quarter of 2018, including revenues (NOK 51.8 million), EBITDA (NOK 1.6 million), and gross margin improvements. It includes commentary from the CEO regarding operational performance, growth strategy, and future outlook. This content structure—summarizing key financial performance for a specific fiscal period (Q4 2018) immediately following the period's end—is characteristic of an Earnings Release (ER). It is not a comprehensive annual report (10-K) or a detailed interim report (IR), but rather the initial announcement of results. Q4 2018
2019-02-14 English
Navamedic ASA: Resultater for fjerde kvartal 2018
Earnings Release Classification · 100% confidence The document is titled "Navamedic ASA: Resultater for fjerde kvartal 2018" (Results for the fourth quarter 2018) and contains key financial metrics (operating revenue, EBITDA, gross margin) for a specific reporting period (Q4 2018). This structure is characteristic of an initial announcement of periodic financial results, focusing on highlights rather than the comprehensive detail found in a full quarterly report (IR) or annual report (10-K). The document explicitly reports the results, making it an Earnings Release (ER). It is too detailed to be a simple Report Publication Announcement (RPA) which usually just announces the availability of a report. Q4 2018
2019-02-14 Norwegian
Navamedic acquires Novicus Pharma
M&A Activity Classification · 99% confidence The document explicitly details the acquisition of Novicus Pharma by Navamedic ASA via a Share Purchase Agreement. It discusses transaction details, consideration paid in new shares, management changes resulting from the acquisition, and is framed as a corporate announcement. This type of event—a merger or takeover proposal—falls directly under the definition of M&A Activity (TAR). It is not an earnings release (ER), a full annual report (10-K), or a general regulatory filing (RNS), as it concerns a specific corporate transaction.
2019-02-13 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.